IOT Innovotech Inc

Innovotech Inc. (TSX VENTURE:IOT), a pioneer in the field of biofilm product
development, today announced its unaudited financial and operational results for
the three and six-month periods ended June 30, 2010.


Highlights:



 - Revenue for first half of 2010 up 46% over 2009                          
 - Innovotech receives funding from Agriculture and Agri-Foods Canada to    
   facilitate commercialization of Agress(TM)                               
 - Extensive 2010 field trial season for Agress(TM)                         



"Innovotech continues to see a demand for its expertise and technology as
demonstrated by the increase in revenue for the first half of the year compared
with the same period for 2009" said Dr. James Timourian, Chief Financial
Officer. "The increase was largely due to significant growth in contract
research revenue and is indicative of the increasing awareness of the role
biofilms play in the world. We expect the revenue growth in contract research to
continue."


The Company has been awarded funding in excess of $900,000 from Agriculture and
Agri-Food Canada to facilitate the commercialization of Agress(TM), its unique,
environmentally friendly seed treatment and plant spray designed to protect
crops against both bacterial and fungal infections. The two-year, repayable
funding will focus on field trials to expand the potential applications of
Agress(TM) from pulse crops (dry beans, dry peas, lentils, chickpeas) and
soybeans to high value horticultural crops such as tomatoes, peppers, and
potatoes. The funding will also be used to support regulatory approval
submissions for Agress(TM). 


The Agress (TM) 2010 crop season marks the most aggressive and diverse field
trial season to date for both Innovotech and its partner, Syngenta. Field
testing is occurring in both bacterial and fungal diseases, and in foliar sprays
and seed treatments. So far, Agress(TM) has met or exceeded expectations.
Innovotech test crops include potatoes, tomatoes, brassica (broccoli,
cauliflower) vegetables, dry beans, and chickpeas. In addition, Syngenta has
extensive field trials occurring in Canada, United States and Europe. 


There is growing international recognition that the Company's test kit bioFILM
PA(TM) can save lives and reduce health care costs. Subsequent to the second
quarter, the Company has signed a distribution agreement for bioFILM PA(TM) with
LevPharm Ltd. to serve the Israeli market and is looking to expand its
availability to counter cystic fibrosis, pneumonia, burn and other stubborn
bacterial infections at home in Canada as well as elsewhere in the world. There
are 35 million susceptibility tests performed each year worldwide, and bioFILM
PA(TM) can replace many of them with more effective results. 


Financial Summary



----------------------------------------------------------------------------
                Three-month     Three-month       Six-month       Six-month 
               period ended    period ended    period ended    period ended 
($)            30 June 2010    30 June 2009    30 June 2010    30 June 2009 
----------------------------------------------------------------------------
Revenues            408,288         373,697         862,658         589,698 
----------------------------------------------------------------------------
G&A                 279,268         251,096         610,732         497,132 
----------------------------------------------------------------------------
R&D                 195,140         208,857         345,558         401,007 
----------------------------------------------------------------------------
Net loss           (261,831)       (287,551)       (491,910)       (654,821)
----------------------------------------------------------------------------
Share Price               -               -            $.66            $.80 
----------------------------------------------------------------------------
Cash                      -               -       1,203,433       1,773,452 
----------------------------------------------------------------------------



About Innovotech Inc.:

Innovotech Inc. is a pioneer in the field of biofilm product development,
focused on providing innovative and practical solutions to medical, agricultural
and industrial problems caused by microbial biofilms. Biofilms are responsible
or a host of diseases in both agriculture and human health due to their inherent
resistance to existing antibiotics and disinfectants. There are currently no
antibiotics, disinfectants, diagnostics or regulatory standards designed
specifically for biofilm-forming organisms.


Innovotech currently has two products in advanced stages of development:
Agress(TM) a unique, environmentally friendly seed treatment and plant spray
designed to protect crops against both bacterial and fungal infections, and
bioFILM PA(TM), the first diagnostic kit to assist physicians in the selection
of the most effective combination of antibiotic treatment of patients with
biofilm-based chronic lung infections.


This document may contain forward-looking statements that are predictive in
nature and subject to risks and uncertainties that cannot be predicted or
quantified; consequently, actual results may differ materially from past results
and those expressed or implied by any forward-looking statements. Factors that
could cause or contribute to such risks or uncertainties include, but are not
limited to: the regulatory environment including the difficulty of predicting
regulatory outcomes; changes in the value of the Canadian dollar; the Company's
reliance on a small number of customers including government organizations;
fluctuations in operating results; government policies or actions; progress and
cost of clinical trials; reliance on key strategic relationships; uncertainty
related to intellectual property protection and potential costs associated with
its defense; the Company's exposure to lawsuits and other matters beyond the
control of management. Should known or unknown risks or uncertainties
materialize, or should management's assumptions prove inaccurate, actual results
could vary materially from those anticipated. The Company undertakes no
obligation to publicly make or update any forward-looking statements, except as
required by applicable law.

Innovotech (TSXV:IOT)
Historical Stock Chart
From Jun 2024 to Jul 2024

Innovotech (TSXV:IOT)
Historical Stock Chart
From Jul 2023 to Jul 2024